Member Info for ant15

Yes I am still buying and have done so both yesterday and today. I am not surprised that the transition as a mindset from wet lab to computer takes as long as it does and quite naturally delays contracts . It has taken 20 years for the FDA to agree the technology and subsequently embrace it. The model is in place and well positioned to be advanced. PYC has a future in an ever expanding sector within the pharmaceutical industry. I have waited patiently for this point in time and will as ever await the rewards it will undoubtedly afford. I am pleased to note the enthusiasm of management of late long may it last. As ever time will tell, take no notice of those that are hell bent on profiteering at this stage and hold for what is an emerging story...not before time but through no fault of their own. The FDA reigns supreme The clock will not be turned back nor the need to produce drugs and dosing regimes economically. Time lines to drug both expensive and time consuming need to be reduced, modelling and computer technology when accurate, present both these possibilities !

I only experienced a little difficulty today but have taken my holding up to 1.7% over the last 20 days and will be buying more Laura.

Following that! been in since Rose days and confident as can be that this will soon rerate. Some de-rampers appearing as expected. Not to worry The drill will be the measure of this shares success nothing else!

"y" not "t" in my last post "busy." clumsy fingers! Its a convoluted story but on a completely different company I was able to forge a bond some years earlier with Main Board Merck Directors that facilitated the first contract for PYC.

I am looking forward to a greater uptake of the technology following the FDA ruling in December 2022 when their latest ACT required the use in part of computer based modelling for drug approval in a move away from animal testing. These things take time to gain traction but I am as sure as I can be that these pressures will now be ramped up by the FDA who will insist on the same and ever increasingly. Not before time as animal rights protestors ( quite justifiably ) have long protested against the use of animals in clinical trials. The technology is out there PYC have a meaningful offering to Pharma Co's. Now is the time to invest in accurate predictive technology as it is rapidly moving to a "must Have " as opposed to a" may be" on a wish list. It will be interesting to see the outcome of their recent presentations. Ant

As an aside poster/investors might want to write on some of the protestors sites promoting PYC as an alternative, they are extremely proactive and not without influence!

DB I think you will find the at PYC has contracted with both. I am open to correction but I believe I'm right. Thanks for all the excellent posts from yourself Laura, Trench et al . We will need some further buy pressure to move up But PYC can and will deliver this with News flow no doubt. Rather bust at present but will revert. Ant

Adon have you any thoughts on flow rates for a successful drill. Thanks ant

Thanks I thought it might be a little higher at around 2500 But even if it it comes in at 1500 barrels a day it will be circa $50 million a year additional income 100% owned. Speculatively in excess of $100 million from the existing portfolio and Paradox and extremely profitable!

Would anyone on the board care to hazard a guess as to potential daily flow rates from this drill Assuming as we all expect and the company believe it will be successful.

Years ago we used Back Web Technology the ability (only when Licenced ) to communicate and input data direct onto 3rd Party Computers in this case Doctors Registered with The NHS to provide updates on alerts and advice for / services / diagnostic tools etc etc. Should the DOSEME RX app be approved and come to market it would be a route to all Doctors in the UK. This market alone is substantial. However I believe that PYC will probably need to "beef up" its sales team to promote it. That said they are in a partnership for the technology and and sales might well be directed by others. If successful the global market opportunity presents exponential growth.

I wouldn't read negativity into this DB. PYC are debt free and remain this way as unlike many on AIM they are not burdened with overly high Directors and management fees frequently linked to Directors abilities to "buy in". I would rather see performance based options and modest salaries as we move forward.

I am pleased to pass on various suggestions as I do but more to see that the company has matured to a point where the present management and directors can really make a difference. I expect news soon and monitor progress closely.

I have been writing an article very recently ( not published as yet) On the NHS This is an aside But clearly Dosing Regimes such as this are not only excellent news for patients but also present significant costs savings too. Drug mis-use primarily over ordering and not using cost The NHS millions each year, potential savings are enormous. So too the use of Generic Drugs which worldwide currently cost Health Service providers in excess of £400 billion a year and projected to rise to over £600 billion by 2030. The NHS has been intransigent but needs to avail itself of all the emergent technologies that diagnostic medical techniques present. As a complete aside We should also have a Government funded Generic GMP facility in the UK The savings would more than warrant its building and operation instead of making some foreign manufacturers incredibly wealthy!

Difficult to buy today?

Trench around 25 years ago Oxford University presented a personalised dosing mechanism to The Royal Society it was primarily designed to be for Diabetes Patients and intended to rely on a Grid they were developing as a secure alternative to "the internet" It was being designed to pass information and control from and to patients. My recollections are scanty save that it attracted offers of serious finance to progress and whilst afforded my offer of funding at the time was frozen out. The availability of Cloud based technology now only serves to enhance this concept. It is this type of "add on" that could really accelerate the take up of DoseMeRX . On the evidence of past experience and as above, there will be significant monies made available by Pharma Cos worldwide as they are all keen to accurately deliver correct dosing regimes on a personalised basis . It may well prove to be the gamechanger here we are all predicting. The time is now right as unlike previously, while a number of us were engaged in thoughts of Personalised medicines then it was a step to far. I don't need to wish shareholders good luck the technology that PYC have at their disposal will provide the answers!

That's a bit of a Broadside Jolly Roger!

Seems as though some are in the know. 25 year Licence looks to have been granted...where's the news from AEX

I notice all the usual suspects are attempting to pull the price down!

With oil about to surge back to $100 a barrel thanks to Saudi cuts in production/ ZPHR about to redrill a known resource to add to their portfolio of producing wells. I am surprised that anyone would want to sell this side of the drill and subsequent flow tests DYOR as always. I've been in since Rose days and this is the best its looked for years!!

I used my name because I founded the company.

You obviously know your stuff ,SPOT ON !

DeBull my wife was a Biotech analyst in The City. Keen to see the company prosper and not just for personal gain she asked me to communicate her willingness to help The Biostats development at PYC. She is also a data analyst and has previously written a paper An Algorithm to predict Protein Protein Binding when at Downing College Cambridge it has ben cited internationally. Cogent in Python and C I asked the Company if they would like some help. We didn't get a reply and I assumed that they had employed all the "muscle" they required. Which is a shame has her contacts extend into the sector where there are numerous opportunities to grow the business. I am not being critical at all but when companies like Avacta are undertaking PK and PD testing in Clinical Trials as indeed OXB we should be banging on their doors. PYC has shown that it understands the need to keep the market better informed and so I look forward to more announcements in the short to medium term. As I previously said DoseMeRX could be a game changer bur as with everything timing is always critical, others will follow suit and USP's and first to market edge are then lost. I have added a few more at these levels it makes sense to me as Personalised Medicine is definitely the way forward.